LEADING A WAVE OF INNOVATION IN PERSONALIZED HEALTHCARe
ABOUT THE COMPANY
Lantern Pharma is reinventing the cancer drug development process by tailoring multiple promising precision drug programs to the right cancer patients using advanced genomics and artificial intelligence (AI) with significantly reduced cost and time. Lantern has in-licensed, validated, de-risked clinical stage drugs that are discontinued for development.Lantern identifies biomarkers for patient response for the drug and further validates by conducting small, focused phase 2 clinical trials to greatly increase the value of each drug, thereby creating multiple exit points for each drug.
Rather than discovering drugs from scratch, Lantern identifies, partners with, licenses or acquires abandoned, late-stage clinical drugs that are effective in only some patients from other companies.
Using advanced genomics, data analytics and Artificial Intelligence (AI), these valuable drugs are 'rescued' and 'repurposed' by using molecular profiling to identify the right patients who will respond positively. Patients will be screened for a response biomarker, stratified and treated in a very small focused clinical trial.
The drug, along with the newly identified biomarker diagnostic for drug response, will be partnered or licensed out to a pharma partner.
-Focused clinical trials to be completed by Lantern Pharma Inc.
-Development of companion diagnostics.